BR112012031232A2 - método, dispositivo e uso - Google Patents
método, dispositivo e usoInfo
- Publication number
- BR112012031232A2 BR112012031232A2 BR112012031232A BR112012031232A BR112012031232A2 BR 112012031232 A2 BR112012031232 A2 BR 112012031232A2 BR 112012031232 A BR112012031232 A BR 112012031232A BR 112012031232 A BR112012031232 A BR 112012031232A BR 112012031232 A2 BR112012031232 A2 BR 112012031232A2
- Authority
- BR
- Brazil
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35324910P | 2010-06-10 | 2010-06-10 | |
EP10165554 | 2010-06-10 | ||
PCT/EP2011/059650 WO2012000770A1 (en) | 2010-06-10 | 2011-06-10 | Methods to diagnose liver diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012031232A2 true BR112012031232A2 (pt) | 2016-10-25 |
Family
ID=42355394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012031232A BR112012031232A2 (pt) | 2010-06-10 | 2011-06-10 | método, dispositivo e uso |
Country Status (7)
Country | Link |
---|---|
US (3) | US9140686B2 (pt) |
EP (3) | EP2580596B1 (pt) |
JP (3) | JP5837581B2 (pt) |
AU (1) | AU2011273748A1 (pt) |
BR (1) | BR112012031232A2 (pt) |
CA (1) | CA2799032A1 (pt) |
WO (1) | WO2012000770A1 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3502707A1 (en) | 2010-01-29 | 2019-06-26 | metanomics GmbH | Means and methods for diagnosing heart failure in a subject |
EP2580596B1 (en) * | 2010-06-10 | 2015-02-25 | Metanomics Health GmbH | Methods to diagnose liver diseases |
WO2012037365A1 (en) * | 2010-09-16 | 2012-03-22 | Quest Diagnostics Investments Incorporated | Mass spectrometric determination of eicosapentaenoic acid and docosahexaenoic acid |
WO2013113992A1 (en) * | 2012-01-31 | 2013-08-08 | Teknologian Tutkimuskeskus Vtt | Method for determining liver fat amount and method for diagnosing nafld |
EP2815237A4 (en) * | 2012-02-15 | 2015-11-04 | Basf Se | MEANS AND METHODS FOR ASSESSING NEURONAL TOXICITY |
EP2822457A4 (en) * | 2012-03-09 | 2015-11-11 | Basf Se | MEANS AND METHODS FOR ASSESSING HYPERTHYROIDISM |
WO2015089102A1 (en) | 2013-12-10 | 2015-06-18 | The Regents Of The University Of California | Differential diagnosis of liver disease |
JP2018502286A (ja) * | 2014-11-19 | 2018-01-25 | メタボロン,インコーポレイテッド | 脂肪肝疾患のバイオマーカーおよびその使用方法 |
WO2016130961A1 (en) * | 2015-02-13 | 2016-08-18 | The Regents Of The University Of California | Methods and compositions for identifying non-alcoholic fatty liver disease |
JP7036805B2 (ja) * | 2016-05-29 | 2022-03-15 | 深▲じぇん▼市▲絵▼云生物科技有限公司 | 肝疾患関連バイオマーカーおよびその使用方法 |
CN109313246A (zh) | 2016-06-13 | 2019-02-05 | 国立大学法人九州大学 | 自由基消耗速度信息的获取方法以及nash的判定方法 |
WO2018007422A1 (en) * | 2016-07-05 | 2018-01-11 | One Way Liver,S.L. | Identification of human non-alcoholic fatty liver disease (nafld) subtypes |
EP3267199A1 (en) * | 2016-07-06 | 2018-01-10 | One Way Liver S.L. | Diagnostic methods based on lipid profiles |
US20200096524A1 (en) * | 2017-02-03 | 2020-03-26 | École Polytechnique Fédérale De Lausanne (Epfl) | Plasma and liver lipid species as biomarkers of fatty liver |
US20200348316A1 (en) * | 2017-11-20 | 2020-11-05 | Zora Biosciences Oy | Methods for prediction and early detection of diabetes |
EP3502703A1 (en) | 2017-12-22 | 2019-06-26 | Metanomics Health GmbH | Method for the assessment of nafld |
EP3759500A4 (en) * | 2018-02-26 | 2021-12-08 | Arizona Board of Regents on behalf of the University of Arizona | EZETIMIB-METABOLIT AS A NON-INVASIVE BIOMARKER FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH) |
US11536726B2 (en) | 2018-04-04 | 2022-12-27 | Metabolon, Inc. | Mass spectrometry assay method for detection and quantitation of liver function metabolites |
CN109060977A (zh) * | 2018-07-13 | 2018-12-21 | 深圳市绘云生物科技有限公司 | 用于肝纤维化和肝硬化诊断的生物标志物和试剂盒及使用方法 |
WO2020066162A1 (ja) * | 2018-09-26 | 2020-04-02 | 株式会社島津製作所 | 非アルコール性脂肪肝疾患の検出方法、非アルコール性脂肪肝疾患検出用キットおよび非アルコール性脂肪肝疾患検出用バイオマーカー |
KR102105880B1 (ko) * | 2018-10-26 | 2020-04-29 | 서울대학교병원 | 비알코올 지방간 질환의 조직학적 중증도 진단 또는 예후 측정에 관한 정보 제공 방법 |
KR102280261B1 (ko) * | 2019-07-16 | 2021-07-20 | 이화여자대학교 산학협력단 | 대사체 분석을 이용한 간질환의 진단 방법 |
KR102171243B1 (ko) * | 2019-08-05 | 2020-10-28 | 한국과학기술연구원 | 행위 중독의 진단용 조성물, 키트 및 이를 이용한 행위 중독의 진단을 위한 인돌-3-락트산의 검출 방법 |
WO2023238881A1 (ja) * | 2022-06-07 | 2023-12-14 | 日東電工株式会社 | 非アルコール性脂肪性肝疾患(nafld)または非アルコール性脂肪肝炎(nash)を診断するためのマーカー |
GB202214670D0 (en) * | 2022-10-06 | 2022-11-23 | Owlstone Med Ltd | Detection of liver disease |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4540884A (en) | 1982-12-29 | 1985-09-10 | Finnigan Corporation | Method of mass analyzing a sample by use of a quadrupole ion trap |
US5397894A (en) | 1993-05-28 | 1995-03-14 | Varian Associates, Inc. | Method of high mass resolution scanning of an ion trap mass spectrometer |
ATE275728T1 (de) * | 1999-01-12 | 2004-09-15 | Ebara Corp | Verfahren und biosensor zum nachweis von antigenen |
WO2003073464A1 (de) | 2002-02-28 | 2003-09-04 | Metanomics Gmbh & Co. Kgaa | Massenspektrometrisches verfahren zur analyse von substanzgemischen |
ES2226549B1 (es) * | 2002-12-18 | 2006-07-16 | One Way Liver Genomics, S.L. | Metodo para el diagnostico de esteatohepatitis no alcoholica (nash) mediante el empleo de marcadores moleculares. |
EP1626279B1 (en) * | 2004-08-12 | 2008-04-16 | Roche Diagnostics GmbH | Method for diagnosing liver fibrosis |
EP1887362A4 (en) * | 2005-05-30 | 2010-01-27 | Ajinomoto Kk | HEPATHOPATHY EVALUATION APPARATUS, HEPATHOPATHY EVALUATION METHOD, HEPATHOPATHY EVALUATION SYSTEM, HEPATHOPATHY EVALUATION PROGRAM, AND RECORDING MEDIUM |
WO2007136822A2 (en) * | 2006-05-19 | 2007-11-29 | George Mason Intellectual Properties, Inc. | Methods to diagnose non-alcoholic steatohepatitis |
BRPI0715402A2 (pt) * | 2006-08-08 | 2013-11-26 | Lipomics Technologies Inc | Marcadores de doença hepática gordurosa não alcoólica (nafld) e esteatohepatite não alcoólica (nash) e métodos de uso dos mesmos |
US20100197028A1 (en) | 2007-02-22 | 2010-08-05 | Tethys Bioscience, Inc. | Metabolic markers of diabetic conditions and methods of use thereof |
WO2008156662A1 (en) * | 2007-06-14 | 2008-12-24 | George Mason Intellectual Properties, Inc. | Methods of diagnosing non-alcoholic steatohepatitis (nash) |
EP2212946B1 (en) * | 2007-10-12 | 2013-02-27 | Toray Battery Separator Film Co., Ltd. | Microporous membranes and methods for making and using such membranes |
WO2009059150A2 (en) | 2007-11-02 | 2009-05-07 | Metabolon, Inc. | Biomarkers for fatty liver disease and methods using the same |
US9186343B2 (en) * | 2007-12-26 | 2015-11-17 | Nanoveson, Llc | Nanoveso™: treatment, biomarkers and diagnostic tests for liver diseases and comorbid diseases |
EP3059592A1 (en) * | 2008-05-28 | 2016-08-24 | Basf Se | Methods for assessing liver toxicity |
DE112009001245T5 (de) * | 2008-05-28 | 2012-03-15 | Basf Se | Mittel und Verfahren für die Beurteilung der Leberenzyminduktion |
WO2009151125A1 (ja) * | 2008-06-13 | 2009-12-17 | 持田製薬株式会社 | 肝障害の診断及び治療 |
JP2011524877A (ja) | 2008-06-18 | 2011-09-08 | ビーエーエスエフ ソシエタス・ヨーロピア | 有害生物の防除に有用な1,2−ベンゾイソチアゾール化合物 |
EP2313773A1 (en) | 2008-07-15 | 2011-04-27 | Metanomics Health GmbH | Means and methods diagnosing gastric bypass and conditions related thereto |
EP2157431A1 (en) * | 2008-08-11 | 2010-02-24 | One Way Liver Genomics, S.L. | Method for the diagnosis of NASH using metabolic profiles |
ES2621838T3 (es) * | 2008-11-18 | 2017-07-05 | Universite D'angers | Método in vitro no invasivo para la cuantificación de lesiones hepáticas |
US10241093B2 (en) * | 2009-05-28 | 2019-03-26 | The Cleveland Clinic Foundation | Trimethylamine-containing compounds for diagnosis and prediction of disease |
CN102472744B (zh) | 2009-08-13 | 2015-11-25 | 巴斯夫欧洲公司 | 诊断甲状腺疾病的手段和方法 |
JP2013508835A (ja) | 2009-10-21 | 2013-03-07 | ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー | バイオマーカー参照パターンを作成する方法 |
AU2010326737A1 (en) | 2009-12-01 | 2012-06-07 | Metanomics Health Gmbh | Means and methods for diagnosing multiple sclerosis |
EP3502707A1 (en) | 2010-01-29 | 2019-06-26 | metanomics GmbH | Means and methods for diagnosing heart failure in a subject |
EP2580596B1 (en) * | 2010-06-10 | 2015-02-25 | Metanomics Health GmbH | Methods to diagnose liver diseases |
US20130295692A1 (en) | 2010-12-23 | 2013-11-07 | Metanomics Health Gmbh | Means and methods for predicting diabetes |
EP2498195A1 (en) * | 2011-03-11 | 2012-09-12 | Centre Hospitalier Universitaire d'Angers | Non-invasive method for assessing the presence or severity of liver fibrosis based on a new detailed classification |
EP2715361A1 (en) | 2011-05-31 | 2014-04-09 | Metanomics Health GmbH | Methods for diagnosing multiple sclerosis |
-
2011
- 2011-06-10 EP EP20110726110 patent/EP2580596B1/en not_active Not-in-force
- 2011-06-10 CA CA 2799032 patent/CA2799032A1/en not_active Abandoned
- 2011-06-10 EP EP15151650.7A patent/EP2863227B1/en not_active Not-in-force
- 2011-06-10 US US13/703,203 patent/US9140686B2/en not_active Expired - Fee Related
- 2011-06-10 EP EP17186813.6A patent/EP3273247A1/en not_active Withdrawn
- 2011-06-10 AU AU2011273748A patent/AU2011273748A1/en not_active Abandoned
- 2011-06-10 JP JP2013513702A patent/JP5837581B2/ja not_active Expired - Fee Related
- 2011-06-10 BR BR112012031232A patent/BR112012031232A2/pt not_active IP Right Cessation
- 2011-06-10 WO PCT/EP2011/059650 patent/WO2012000770A1/en active Application Filing
-
2015
- 2015-08-18 US US14/828,925 patent/US10001468B2/en not_active Expired - Fee Related
- 2015-11-05 JP JP2015217309A patent/JP6141387B2/ja not_active Expired - Fee Related
-
2017
- 2017-05-02 JP JP2017091496A patent/JP2017167153A/ja not_active Ceased
-
2018
- 2018-05-18 US US15/983,950 patent/US20180267018A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2011273748A1 (en) | 2012-12-06 |
WO2012000770A1 (en) | 2012-01-05 |
JP5837581B2 (ja) | 2015-12-24 |
CA2799032A1 (en) | 2012-01-05 |
JP2013533471A (ja) | 2013-08-22 |
US20130126722A1 (en) | 2013-05-23 |
EP2580596B1 (en) | 2015-02-25 |
US10001468B2 (en) | 2018-06-19 |
EP2863227A1 (en) | 2015-04-22 |
EP2580596A1 (en) | 2013-04-17 |
US20150355197A1 (en) | 2015-12-10 |
EP3273247A1 (en) | 2018-01-24 |
JP6141387B2 (ja) | 2017-06-07 |
US20180267018A1 (en) | 2018-09-20 |
JP2017167153A (ja) | 2017-09-21 |
US9140686B2 (en) | 2015-09-22 |
EP2863227B1 (en) | 2017-09-27 |
JP2016065873A (ja) | 2016-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012031232A2 (pt) | método, dispositivo e uso | |
BR112013012055A2 (pt) | dispositivo de fenestação, sistemas e métodos | |
BR112013007506A2 (pt) | piridinonas/pirazinonas - métodos de criação e de uso | |
BR112013008522A2 (pt) | dispositivo de comunicação e método de comunicação | |
BR112013009489A2 (pt) | aparelho e método de conexão | |
BR112013010725A2 (pt) | método, e, composição | |
BR112012018101A2 (pt) | aparelho, e método. | |
BR112012002349A2 (pt) | composto,e, uso do mesmo | |
DK2577890T3 (da) | Multi-registrerings-OTDR-fremgangsmåde og -indretning | |
BR112013033888A2 (pt) | dispositivo e método de comunicação | |
BR112013011412A2 (pt) | aparelho de navegação e método | |
BRPI0913752A2 (pt) | método, dispositivo, e, estrutura | |
BR112012027159A2 (pt) | estrutura e método | |
DK3388687T3 (da) | Spændingsapplikationsindretning, rotationsapparat og spændingsapplikationsfremgangsmåde | |
BR112012016424A2 (pt) | aparelho, e método. | |
BR112013009494A2 (pt) | condicionador, aparelho e método | |
FI20105534A0 (fi) | Katkaisu- ja pilkkomislaite | |
IT1398416B1 (it) | Dispositivo elettrovalvolare. | |
BRPI1006996A2 (pt) | composição, método e uso | |
BR112014009178A2 (pt) | métodos, uso, receptor e invenção | |
FI20105906A0 (fi) | Laite | |
BR112013012248A2 (pt) | dispositivo e método para imunotestes | |
BR112013012175A2 (pt) | combinação, coadministração, uso e método | |
BR112013022541A2 (pt) | dispositivo e método de recepção, e, programa | |
BR112013003640A2 (pt) | método, acelerômetro, e aparelho |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |